Return to search results.
Complete title: A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Melanoma
|Research Study Number||9103A|
|Principal Investigator||Kim Margolin, MD|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Melanoma; Solid Tumors; Neuroendocrine Tumor
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.